Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex

Cancer Discovery(2025)10.1158/2159-8290.cd-25-0271Source: DataRank Database

Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex is a research paper published in Cancer Discovery (2025). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

cellosaurus ensembl dbgap alphafold uniprot pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 2.03)OA: hybridTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (6)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Wenzhi Ji ORCID,Brendan G. Dwyer ORCID,Joey Lu ORCID,Jing Bian ORCID,Gianna M. Colombo ORCID

Live enrichment

PubMed:40891634 PMC:PMC12670082 OpenAlex:https://openalex.org/W4413930774

Damon Runyon Cancer Research Foundation

Grant: CI 128-24

National Institutes of Health

Grant: K08CA230220

National Institutes of Health

Grant: R01CA272485

National Institutes of Health

Grant: T32GM139791

National Institutes of Health

Grant: S10OD030332

National Institutes of Health

Grant: P30GM133894

NCI NIH HHS

Grant: P30 CA124435

Shmunis Family Innovation Award in Cancer Therapeutics

School of Medicine Dean's Postdoctoral Fellowship

Lowell Berry Foundation

School of Medicine Dean’s Postdoctoral Fellowship

c-ShaRP Voucher Program

FWCI

2.03

Citation Percentile

0.9%

Citation Trend

2026

hybridLicense: cc-by-nc-nd

journalhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-25-0271/3647438/cd-25-0271.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-25-0271/3647438/cd-25-0271.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-25-0271/3665526/cd-25-0271.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/15/12/2505/3684538/cd-25-0271.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-25-0271

Fields of Study

Nuclear Structure and FunctionRetinoids in leukemia and cellular processesProtein Degradation and Inhibitors

MeSH Terms

SS-A AntigenAnimalsAntineoplastic AgentsHumansPancreatic NeoplasmsRibonucleoproteinsNuclear PoreXenograft Model Antitumor AssaysCell Line, TumorMice

Keywords

Nuclear poreUbiquitin ligaseNucleoporinCell biologyUbiquitinPhenotypeCytoplasmCancer researchChemistryCell cultureBiologyProteomicsNuclear proteinComputational biologyMolecular biologyNuclear transportBiochemistryCell nucleusGeneticsGeneTranscription factor

Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex

FAIR Checklist

Authors (28)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)